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Abstract Patients with acute medical illnesses are at
increased risk of venous thromboembolism (VTE), a sig-
niﬁcant cause of morbidity and mortality. Thrombopro-
phylaxis is recommended in these patients but questions
remain regarding the optimal duration of therapy. The aim
of this study is to determine whether oral rivaroxaban is
non-inferior to standard-duration (approximately 10 days)
subcutaneous (s.c.) enoxaparin for the prevention of VTE
in acutely ill medical patients, and whether extended-
duration (approximately 5 weeks) rivaroxaban is superior
to standard-duration enoxaparin. Patients aged 40 years or
older and hospitalized for various acute medical illnesses
with risk factors for VTE randomly receive either s.c.
enoxaparin 40 mg once daily (od) for 10 ± 4 days or oral
rivaroxaban 10 mg od for 35 ± 4 days. The primary efﬁ-
cacy outcomes are the composite of asymptomatic proxi-
mal deep vein thrombosis (DVT), symptomatic DVT,
symptomatic non-fatal pulmonary embolism (PE), and
VTE-related death up to day 10 ? 4 and up to day 35 ? 4.
The primary safety outcome is the composite of treatment-
emergent major bleeding and clinically relevant non-major
bleeding. As of July 2010, 8,101 patients from 52 countries
have been randomized. These patients have a broad range
of medical conditions: approximately one-third were
diagnosed with acute heart failure, just under one-third
were diagnosed with acute infectious disease, and just
under one-quarter were diagnosed with acute respiratory
insufﬁciency. MAGELLAN will determine the efﬁcacy,
safety, and pharmacological proﬁle of oral rivaroxaban for
the prevention of VTE in a diverse population of medically
ill patients and the potential of extended-duration therapy
to reduce incidence of VTE.
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Venous thromboembolism (VTE) comprises deep vein
thrombosis (DVT) and pulmonary embolism (PE). Short-
term (1–2 weeks) thromboprophylaxis with anticoagulants
has resulted in a reduction of both non-fatal and fatal PE in
medical and surgical patients [1–3]. Extended-duration
regimens in surgical patients have successfully reduced the
incidence of VTE compared with placebo [4] or the current
standard of care [5–9], and their use is recommended in
clinical guidelines [4, 10]. Little is known about extended-
duration regimens in medical patients.
Approximately three-quarters of all in-hospital deaths
from PE occur in medical patients [11], and the prevalence
of asymptomatic and symptomatic DVT in hospitalized
medical patients not receiving thromboprophylaxis is
between 10 and 20% [4]. Acute medical conditions, such as
acute heart failure, acute infection, acute respiratory fail-
ure, stroke, and myocardial infarction, are known to put
patients at increased risk of VTE [12, 13], and most con-
ditions that require prolonged immobilization also repre-
sent a temporary excess risk of VTE [12]. Other risk factors
include age over 75 years, chronic heart failure, cancer and
chemotherapy, prior VTE, obesity, varicose veins, and
thrombophilia [12–16].
Large randomized clinical trials that have demonstrated
the effectiveness of short-term pharmacologic thrombo-
prophylaxis in acutely ill medical patients showed reduc-
tions in the relative risk of VTE of between 45 and 64% [2,
17–19]. The results of these trials formed the basis of
guideline recommendations for the use of unfractionated
heparin, low-molecular-weight-heparins (LMWHs), or
fondaparinux in this patient population [4].
Although guidelines recommend anticoagulant use in
acutely ill medical patients, their use is not routine in
clinical practice. International registry and epidemiological
data have shown that approximately 50% of at-risk acutely
ill medical patients receive any form of prophylaxis, and
that less than 40% receive prophylaxis in line with
recommendations from the American College of Chest
Physicians (ACCP) guidelines [20, 21].
There is evidence that the risk of VTE in acutely ill
medical patients persists beyond hospital discharge. In the
MEDENOX study, where prophylaxis or placebo were
administered for 10 ± 4 days, eight venous thromboem-
bolic events (7.8% of the total) occurred between days 15
and 110, of which four were fatal PEs [17]. More recently,
the EXCLAIM study demonstrated that extended-duration
enoxaparin (38 ± 4 days), compared with placebo after
open-label standard-duration enoxaparin (10 ± 4 days),
signiﬁcantly reduced the overall incidence of VTE (abso-
lute risk difference, -1.53% [95.8% conﬁdence interval
[CI], -2.54 to –0.52%]) in acutely ill medical patients with
reduced mobility, but with a signiﬁcant increase in the
incidence of major bleeding (absolute risk difference,
0.51% [95% CI, 0.12 to 0.89%]) [22].
Rivaroxaban is an oral, direct Factor Xa inhibitor
approved in many countries worldwide for the prevention
of VTE after elective hip and knee replacement surgery in
adult patients. Rivaroxaban has a fast onset and offset of
action, and has been shown to have predictable pharma-
cokinetics (PK) and pharmacodynamics (PD) and a low
propensity for drug–drug interactions [23].
MAGELLAN (Multicenter, rAndomized, parallel Group
Efﬁcacy and safety study for the prevention of VTE in
hospitalized acutely iLL medical patients comparing riva-
roxabAN with enoxaparin) was designed to assess both the
efﬁcacy and safety of oral rivaroxaban compared with
standard-duration subcutaneous (s.c.) enoxaparin, and to
evaluate the role of extended-duration (approximately
5 weeks) thromboprophylaxis in acutely ill medical
patients.
Study objectives
The objectives of the study are twofold: ﬁrstly, to determine
whether oral rivaroxaban 10 mg once daily (od) for
10 ± 4 daysisnon-inferiortos.c.enoxaparin(40 mgod)for
10 ± 4 days for the prevention of VTE in patients aged
40 years or older and hospitalized for a medical illness;
secondly, to determine whether oral rivaroxaban 10 mg od
for 35 ± 4 days is superior to s.c. enoxaparin 40 mg od for
10 ± 4 days (placebo continued until day 35 ± 4), in the
same patient population. The principal safety objective is
to compare the safety of rivaroxaban administered for
35 ± 4 dayswithenoxaparinadministeredfor10 ± 4 days.
Methods
Study design
MAGELLANisaprospective,randomized,blinded(patient,
care-giver, data-collector, and outcome-assessor), double-
dummy, active comparator-controlled, multicenter, multi-
nationalclinicaltrialinacutelyillmedicalpatients. Thetrial
is being conducted in accordance with the Declaration of
Helsinki and local regulations. Approval of the protocol was
obtained from the appropriate ethics committee or institu-
tional review board for all participating centers.
Setting
As of July 2010, 8,101 patients have been randomized in
556 centers from 52 countries (Table 1).
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Subjects are considered for enrollment if they are hospi-
talized for a speciﬁed acute medical illness, have a risk of
VTE (reduced mobility with conditions as speciﬁed in
inclusion criteria; Table 2), and their anticipated survival
time is more than 6 months. Patients with acute infectious,
inﬂammatory, or rheumatic diseases, and those with acute
respiratory insufﬁciency, also require one or more well-
characterized risk factors for VTE, such as a history of
VTE or cancer [16, 24, 25]. All patients are required to
give written informed consent. Patients are excluded from
the study if they have conditions that contraindicate the use
of enoxaparin or rivaroxaban. Patients are also excluded if
they have certain concomitant conditions or diseases,
including conditions that may increase the risk of bleeding,
or if they require certain drugs or procedures (examples
listed in Table 2).
Treatment regimens
Patients meeting the entry criteria are stratiﬁed by center
using permuted blocks (size 4) and randomized using an
interactive voice response system to allocate the blinded
study medication. Patients are randomized to receive either
s.c. enoxaparin 40 mg od for 10 ± 4 days and oral riva-
roxaban placebo for 35 ± 4 days, or oral rivaroxaban
10 mg od for 35 ± 4 days and s.c. enoxaparin placebo for
10 ± 4 days. The active treatment period for the enoxap-
arin arm is from day 1 to day 10 ± 4 and for the riva-
roxaban arm is from day 1 to day 35 ± 4 (day 1 is deﬁned
as the day of randomization). Patient follow-up continues
until day 90 ± 7 (Fig. 1).
Table 1 Number of sites enrolled by participating countries
Geographic region and countries Number of
sites enrolled
Africa: total 14
South Africa 14
Asia: total 121
China 43
Hong Kong 2
India 14
Indonesia 3
Japan 32
Korea 7
Malaysia 3
Pakistan 3
Singapore 6
Taiwan 5
Thailand 3
Australia and New Zealand: total 14
Australia 11
New Zealand 3
Europe: total 278
Austria 14
Belgium 10
Bulgaria 8
Croatia 6
Czech Republic 7
Denmark 5
Estonia 4
Finland 2
France 22
Germany 27
Greece 10
Hungary 8
Israel 10
Italy 21
Latvia 6
Lithuania 10
Luxembourg 2
The Netherlands 4
Norway 4
Poland 14
Portugal 10
Russia 8
Slovakia 5
Slovenia 6
Spain 11
Sweden 9
Switzerland 6
Turkey 6
Ukraine 16
Table 1 continued
Geographic region and countries Number of
sites enrolled
United Kingdom 7
North America: total 97
Canada 13
Mexico 12
United States 72
South America: total 32
Argentina 7
Brazil 8
Chile 2
Colombia 8
Peru 7
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123Table 2 Principal inclusion and exclusion criteria for MAGELLAN
Inclusion criteria Exclusion criteria
Patients aged C40 years Conditions that contraindicate the use of the LMWH enoxaparin
Patients at risk of venous thromboembolic events being
hospitalized
for acute medical conditions as follows:
Heart failure, NYHA class III or IV
Active cancer (e.g. admitted for chemotherapy or for treatment
of a complication of the active cancer)
Acute ischemic stroke
Acute infectious and inﬂammatory diseases, including acute
rheumatic diseases
Acute respiratory insufﬁciency
Patients with at least one additional risk factor for VTE:
Severe varicosis
Chronic venous insufﬁciency
History of cancer
History of DVT or PE
History of heart failure NYHA class III or IV
Thrombophilia (hereditary or acquired)
Recent major surgery (6–12 weeks)
Recent serious trauma (6–12 weeks)
Hormone replacement therapy
Advanced age C75 years
Morbid obesity (body mass index C35 kg/m
2)
Acute infectious disease contributing to hospitalization
Additional risk factor not required for patients with:
Heart failure NYHA class III/IV with previous hospitalizations
for heart failure NYHA class III/IV or chronic NYHA
class III/IV status
Active cancer
Acute ischemic stroke with lower extremity paresis or paralysis
Anticipated complete immobilization
a for C1 day during the
hospitalization and anticipated decreased level of mobility
b
for C4 days after randomization in any type of care setting
(e.g. hospital, intermediate care or rehabilitation centre, managed
care in home, etc.) and additional anticipated
ongoing decreased mobility
c thereafter
Hospitalized\72 h before randomization
Bleeding risk-related criteria:
Clinically signiﬁcant bleeding, within 30 days of randomization
Major surgery, biopsy of a parenchymal organ, ophthalmic surgery,
or serious trauma within 6 weeks before randomization
A presenting diagnosis for which surgery is intended during hospitalization
Known coagulopathy or bleeding diathesis or an INR[1.5 at the time
of screening unrelated to VKA therapy
History of hemorrhagic stroke at any time in the past, evidence of primary
intracranial hemorrhage on CT or MRI scan of the brain, or clinical
presentation consistent with intracranial hemorrhage
Recent severe head trauma within 30 days of randomization
Known intracranial neoplasm, cerebral metastases, arteriovenous
malformation, or aneurysm
Concomitant conditions or diseases, such as:
Known allergy to rivaroxaban or any of its excipients
Severe renal insufﬁciency
Known signiﬁcant liver or LFT abnormalities that would require study
medication discontinuation
Known HIV infection at screening
Sustained uncontrolled systolic blood pressure of C180 mmHg or diastolic
pressure of C100 mmHg at time of screening despite treatment
History of ongoing drug or alcohol abuse
Cardiogenic or septic shock with the need for vasopressor(s)
Pregnancy or breastfeeding or any plan to become pregnant during the
study
Required drugs or procedures, such as:
[2 days of prophylactic use of anticoagulants
Systemic treatment with more than two doses of strong inhibitors
of cytochrome P450 3A4, such as ketoconazole or protease inhibitors,
within 4 days before randomization or planned treatment during the time
period of study drug administration
Indication for ﬁbrinolysis or need for continued treatment with
anticoagulant agents for more than 14 days
Treatment with or use of mechanical thromboprophylaxis
(e.g. pneumatic compression devices, foot pumps)
for VTE prevention
CT computed tomography, DVT deep vein thrombosis, HIV human immunodeﬁciency virus, INR international normalized ratio, LFT liver
function test, LMWH low-molecular-weight-heparin, MRI magnetic resonance imaging, NYHA New York Heart Association, PE pulmonary
embolism, VKA vitamin K antagonist, VTE venous thromboembolism
a Complete immobilization: the patient is totally conﬁned by his or her illness to bed or chair. The patient may be allowed to use a bedside
commode or with assistance may be allowed bathroom privileges
b Decreased mobility: immobilization caused by the illness requiring the patient to remain in bed or chair more than 50% of the time during
daytime hours
c Ongoing decreased mobility: immobilization caused by the illness requiring the patient to remain in bed or chair during daytime hours more
than was normal and usual for the patient prior to hospitalization
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Hospital unit and ward characteristics are recorded. During
the screening period, a medical history is obtained. A
physical examination, an electrocardiogram, a pregnancy
testforwomen of childbearing potential and blood sampling
for clinical chemistry (electrolytes, renal and liver function,
and NT-proBNP), hematology (complete blood count), and
coagulation (prothrombin time, prothrombinase-induced
clotting time [PiCT
; Pentapharm, Basel, Switzerland],
and D-dimer) are also performed. During the baseline
(day 1 visit), rivaroxaban and matching placebo are admin-
isteredorallywithorwithoutfood;enoxaparinandmatching
placebo are administered subcutaneously.
For those subjects who give informed consent for the
pharmacogenetic part of the study, a blood sample for
pharmacogenetic analysis is taken (a retention sample is
also taken). For subjects enrolled at selected centers, and
willing to participate in the full PK/PD proﬁle part of the
study, blood samples are drawn before the ﬁrst dose of
study medication and at 1, 2, 3, 4, 6, 9, and 12 h post-dose.
Suspected cases of DVT are evaluated by bilateral lower
extremity venous ultrasonography or other vascular imag-
ing procedures of the lower extremities, e.g. venography.
Suspected cases of PE are evaluated by thoracic spiral
computed tomography, a ventilation perfusion lung scan
with chest X-ray, or pulmonary angiography. If the diag-
nosis of DVT or PE is not conﬁrmed, subjects continue to
receive study medication. Mandatory routine bilateral
lower extremity venous ultrasonography is performed after
the last dose of study medication or matching placebo on
day 10 ± 4 and on day 35 ± 4, within 24 h of their
administration. In subjects prematurely discontinuing their
treatment, bilateral ultrasonography is performed at that
time and at day 35 ± 4. Patients are assessed on
day 90 ± 7 for adverse events, symptomatic VTE,
bleeding events, acute myocardial infarction, acute ische-
mic stroke, and death. Clinical chemistry is also performed
for liver function testing. Symptoms of DVT or PE
occurring during follow-up are veriﬁed by appropriate
diagnostic testing as described above.
Efﬁcacy and safety outcomes
There are two primary efﬁcacy outcomes: the incidence of
thecompositeofasymptomaticproximalDVT,symptomatic
DVT (proximal or distal), symptomatic non-fatal PE,
and VTE-related death from day 1 to day 10 ? 4 (test for
non-inferiority); and the incidence of this composite
outcome from day 1 to day 35 ? 4 (test for superiority).
The secondary efﬁcacy outcomes are the incidence of the
composite of asymptomatic proximal DVT, symptomatic
DVT, symptomatic non-fatal PE, and all-cause mortality up
to day 10 ? 4 and day 35 ? 4 (major secondary outcome);
symptomatic VTE up to day 10 ? 4, day 35 ? 4, and
day 90 ? 7; and all-cause mortality up to day 90 ? 7. Net
clinical beneﬁt will be assessed by the composite outcome
of asymptomatic proximal DVT, symptomatic DVT,
symptomatic non-fatal PE, VTE-related death, treatment-
emergent major bleeding, and non-major clinically relevant
bleedinguptoday10 ? 4andday35 ? 4.Theincidenceof
each component of the primary efﬁcacy outcomes and the
composite of cardiovascular death, acute myocardial
infarction, or acute ischemic stroke up to day 10 ? 4,
day 35 ? 4, and day 90 ? 7 are also secondary outcomes.
The primary safety outcome is the incidence of the
composite of treatment-emergent major bleeding and non-
major clinically relevant bleeding observed not later than
2 days after the last intake of study medication. Bleeding
events are deﬁned in Table 3. Bleeding events observed
more than 2 days after the last intake of study medication
will be considered separately. Minimal bleeding events,
Fig. 1 MAGELLAN study design.
a Heart failure (New York Heart Association class III or IV), active cancer, acute ischemic stroke, acute
infectious, acute inﬂammatory diseases or acute rheumatic diseases, or acute respiratory insufﬁciency. od once daily
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teria for major bleeding or non-major clinically relevant
bleeding events, will also be summarized. Other safety
outcomes include treatment-emergent adverse events and
abnormal laboratory parameters.
PK and PD parameters
A target of 125 patients willing to participate in a full
PK/PD proﬁle will be stratiﬁed into ﬁve groups of 25
patients for the major diagnostic groups.
Based on the plasma concentration–time data, PK
parameters of rivaroxaban will be calculated on day 1 and
day 10 ± 4 for the data-rich proﬁle obtained in this subset
of patients. These parameters include area under the curve,
maximum concentration of drug in plasma, elimination
half-life, and apparent clearance.
Pharmacogenetics
The pharmacogenetic assessment allows analysis of genes
involved in the absorption, distribution, metabolism, and
excretion of the study drug. Genes involved in coagulation,
thrombotic diseases, treatment response, and safety could
also be evaluated. No prospective analyses are planned for
the pharmacogenetic samples in the study, and samples will
be stored and analyzed only if other data collected in the
study result in a hypothesis that can be tested by genetic
analysis.
Health economics outcome research
Healthcare resource utilization is evaluated and includes
primaryhospitalization typeandduration,re-hospitalization
and emergency room visits, healthcare professional visits,
outpatient surgery and consultations, and need for inpatient
or outpatient rehabilitation or skilled nursing facility stay.
Quality of life measures (EQ-5D [European Quality of Life]
questionnaire) and patient-reported outcomes (SF-12 [Short
Form] survey) are also being collected.
Statistical analyses and sample size
A statistical analysis plan has been completed. Subjects are
valid for the safety analysis if at least one dose of study
medication is administered. Two efﬁcacy analysis popu-
lations are deﬁned, both for the non-inferiority analysis and
for the superiority analysis. In both populations, patients
are eligible for the modiﬁed intention-to-treat (mITT)
analysis if they are valid for the safety analysis and have an
adequate assessment of VTE, deﬁned as an adequate
assessment of DVT or PE, if applicable. Patients are
eligible for the per-protocol analysis if they are valid for
the mITT analysis, have an adequate assessment of VTE
Table 3 Deﬁnitions of bleeding events
Deﬁnition
Major bleeding [42]
Bleeding leading to a C2 g/dl fall in hemoglobin or a transfusion of C2 units of packed red blood cells or whole blood
Bleeding into a critical site (intracranial, intraspinal, intraocular, retroperitoneal, intra-articular, pericardial, or intramuscular with
compartment syndrome), or
Bleeding leading to death
Non-major clinically relevant bleeding
Overt bleeding not meeting the criteria for major bleeding but associated with medical intervention, unscheduled contact with a physician,
temporary cessation of study treatment or discomfort for the subject such as pain, or impairment of activities of daily life
Examples include:
Any bleeding compromising hemodynamics
Any bleeding leading to hospitalization
Subcutaneous skin hematoma[25 cm
2 or 100 cm
2 if provoked
Intramuscular hematoma
Epistaxis (lasting[5 min), if it is repetitive or leads to an intervention
Gingival bleeding if it occurs spontaneously or if it lasts[5 min
Hematuria if it is macroscopic and either spontaneous or lasts for[24 h after instrumentation (e.g. catheter placement or surgery) of the
urogenital tract
Macroscopic gastrointestinal hemorrhage: at least one episode of melena/hematomesis, if clinically apparent and hemoccult positive
Rectal blood loss, if more than a few spots on toilet paper
Hemoptysis, if more than a few speckles in the sputum and not occurring within the context of pulmonary embolism
Any other type of bleeding that is considered to have clinical consequences for a patient
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study drug, meet the inclusion criteria, and have no major
protocol violations.
Sensitivity analyses will be performed for the primary
efﬁcacy endpoint considering all randomized subjects. A
method described for the analysis of a binary composite
endpoint with missing data in components will be used
[26]. The two components of the binary composite end-
point will be the assessment of an asymptomatic proximal
DVT from the bilateral lower extremity venous ultrasonog-
raphy and the assessment of symptomatic lower extremity
DVT (proximal or distal), symptomatic non-fatal PE,
or VTE-related death. The latter assessment will be consid-
ered to have been evaluated in all subjects because it
is assumed that such an event would have been reported if
it occurred. The former assessment will be considered to
have been evaluated in all subjects with evaluable
ultrasonography (within the assessment period). This
approach derives the probabilities of the outcomes and
constructs the overall rate based on the estimated probabil-
itiesofthetwocomponents.A95%asymptotic(unstratiﬁed)
conﬁdence interval around the relative risk will be
calculated.
Efﬁcacy analysis
Allstatisticaltestswillbeone-sidedwithatypeIerrorrateof
2.5%; two-sided 95% CIs will be given. A multiple testing
approach will be employed to evaluate the two primary
efﬁcacy outcomes [27]. If the test for non-inferiority at day
10 ? 4 is met, a test for superiority will be applied using the
method described for the primary efﬁcacy outcomes. If both
primary outcomes are signiﬁcant at the one-sided level
(2.5%) then both outcomes can be declared statistically
signiﬁcant. If one P-value is greater than 2.5%, the P-value
for the other primary outcome must be less than 1.25%
before signiﬁcance for this outcome can be declared.
For both primary efﬁcacy outcomes, the relative risk
ratio of the incidence rates (rivaroxaban/enoxaparin) will
be estimated based on a stratiﬁed Mantel–Haenszel model
(stratiﬁed by geographic region). The primary analysis
population for superiority will be the mITT population. The
primary analysis population for non-inferiority will be the
per-protocol population.
The secondary outcomes of the composite of asymp-
tomatic proximal DVT, symptomatic DVT, symptomatic
non-fatal PE, and all-cause mortality up to day 35 ? 4, and
adverse events will be analyzed in the same way as the
primary outcomes. The outcomes of symptomatic VTE and
death will be analyzed in the safety population; the hazard
ratios (rivaroxaban/enoxaparin) will be estimated based
on a stratiﬁed proportional hazards model (stratiﬁed by
geographic region).
Safety analysis
All statistical tests will be two-sided with a type I error rate
of 5%; two-sided 95% CIs will be given. The incidence of
the composite of major bleeding and non-major clinically
relevant bleeding and the incidence of major bleeding will
be analyzed as described for the primary efﬁcacy out-
comes. All other safety data will be analyzed descriptively.
No interim analysis was planned after the ﬁrst amend-
ment to the protocol. The introduction of the mandatory
lower extremity vascular ultrasonography on day 10 ± 4
mitigated the need for an interim analysis because of a
safety concern because all patients with proximal asymp-
tomatic leg thrombosis would be identiﬁed and treated as
required if detected during the day 10 ± 4 period.
Exploratory analyses
Theincidenceratesoftheprimaryefﬁcacyendpointsandthe
major secondary endpoint ineach treatment groupas well as
the relative risk and the corresponding non-stratiﬁed
exact two-sided 95% CIs will additionally be assessed by
geographic region and country as well as by demographic
variables and other covariates.
Determination of sample size
The determination of sample size takes into account the
assumptions for both primary efﬁcacy outcomes and allows
for a joint power of at least 90%. A sample size of 2,876
valid patients per group was estimated based on the fol-
lowing assumptions: a 2.2% event rate in the control group
at day 10 ? 4[ 17–19], a relative reduction of at least 35%
in event rate with rivaroxaban at day 10 ? 4, a 4% event
rate in the control group at day 35 ? 4[ 17–19, 28], a
relative reduction of at least 40% in event rate with riva-
roxaban at day 35 ? 4, and a joint probability of a type II
error of less than 10%. Assuming an invalidity rate of up to
20–30%, the total sample size of randomized subjects is
7,190–8,220. The sample size estimate assumes a non-
inferiority margin of 1.5 based on the lower 95% conﬁ-
dence bound for the relative risk of placebo versus active
treatment in a meta-analysis of three placebo-controlled
trials in acutely ill medical patients [12].
PK and PD
Descriptive statistics will be calculated for plasma con-
centration parameters. Exploratory analyses will be per-
formed to relate coagulation parameters to bleeding events
and to relate coagulation parameters to venous thrombo-
embolic events.
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To assess asymptomatic proximal DVT, bilateral ultraso-
nography of the proximal veins of the lower extremity is
performed in all subjects. Veins identiﬁed are the common
femoral vein, the deep femoral vein, the superﬁcial femoral
vein, the popliteal vein, and the trifurcation of the calf
veins.
The lack of compressibility of a vein under probe
pressure is considered to be the primary criterion for the
demonstration of thrombosis. Compression maneuvers with
the ultrasonography transducer in the transverse plane are
performed at 2–3 cm intervals along the veins studied. The
ultrasonography examination is adequate if all vein seg-
ments are documented by appropriately annotated contin-
uous recordings or still images, and allows the assessment
of compressibility for each of the required veins. An
Ultrasonography Adjudication Committee (UAC) adjudi-
cates all scheduled and unscheduled ultrasonographies
performed during the treatment period in a blinded manner.
The adjudication of the UAC is the basis for the ﬁnal
primary efﬁcacy analysis.
Clinical events procedures
A Clinical Events Adjudication Committee centrally
adjudicates and/or classiﬁes the primary and secondary
efﬁcacy and safety (all bleeding) clinical events.
Protocol amendments
Modiﬁcations to the study protocol were only implemented
with agreement from both the sponsor and the Steering
Committee.
After discussion with the health authorities, the follow-
ing changes were made to the study protocol via its ﬁrst
amendment. Patients with diabetes mellitus or patients who
would fall into the broad category of having ‘other’ medical
illnesses were excluded. For patients with acute infectious,
inﬂammatory and rheumatic diseases, and acute respiratory
insufﬁciency, one or more additional risk factors for VTE
were stipulated as a requirement for inclusion in the study.
In addition, the required duration of immobilization was
extended to beyond the 4 days of hospitalization, and a
secondroutine lower extremity venous ultrasonography was
added to patient assessment, performed at the time of par-
enteral study medication discontinuation (day 10). This
efﬁcacy outcome was to test for non-inferiority of riva-
roxaban compared with enoxaparin for efﬁcacy.
Further amendments included the addition of acute
infectious disease contributing to hospitalization as an
inclusion criterion and increasing the period of hospital-
ization before randomization from 48 to 72 h. Hospital stay
and duration vary widely between countries for patients
with identical admitting diagnoses and the venue of
immobilization required for inclusion of a patient was
expanded to any type of healthcare setting.
Current status of the study
As of July 2010, 8,101 patients were included in the study
and enrollment was stopped. The last patient visits took
place in October 2010.
The patients cover a broad age range (40–105 years) and
have a diverse range of primary diagnoses (Table 4).
Discussion
MAGELLAN will be the ﬁrst randomized clinical trial of
VTE prevention in acutely ill medical patients to directly
compare rivaroxaban, a new generation oral anticoagulant,
with s.c. enoxaparin administered for 10 ± 4 days. The
active comparator phase of this study will allow an unbi-
ased comparison of rivaroxaban with enoxaparin and will
also provide insight into the potential beneﬁts of oral
compared with s.c. thromboprophylaxis administration.
MAGELLAN will also assess the efﬁcacy and safety of
extended-duration thromboprophylaxis with rivaroxaban.
There is strong evidence for the beneﬁts of extended-
duration thromboprophylaxis in elective abdominal cancer
surgery [29, 30] and in hip replacement [31–33] and frac-
ture surgery [34]. The use of extended-duration LMWH
thromboprophylaxis up to 35 days is well established in
these surgeries. Recently, oral rivaroxaban 10 mg od
administered for 35 days was shown to signiﬁcantly reduce
the incidence of VTE in patients undergoing total hip
replacement surgery compared with s.c. enoxaparin
40 mg od administered for 35 days [5].
The rivaroxaban dose selected for use in the MAGELLAN
study was based on phase II studies in orthopedic surgery,
Table 4 Primary diagnosis of subjects in the MAGELLAN study
safety population
Subject characteristics
Number of subjects in the safety population 7998
Primary diagnosis (%)
a
Acute infectious and inﬂammatory disease 47.3
Acute heart failure 32.4
Acute respiratory insufﬁciency 28.0
Acute stroke 17.3
Active cancer 7.3
Other diseases 0.7
a Patients could have more than one primary diagnosis
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123which demonstrated rivaroxaban 10 mg od had comparable
efﬁcacy and safety to enoxaparin 40 mg od; phase III
studies conﬁrmed this [5, 6, 8, 35, 36]. The enoxaparin
regimen chosen for the comparator group is approved for
use in all participating countries [37].
In the current study, asymptomatic VTE is diagnosed
using a standardized ultrasonography protocol, as ﬁrst
utilized in the PREVENT study [18]. The advantages of
ultrasonography compared with venography are that it is
convenient, readily available, non-invasive, repeatable,
and does not expose patients to ionizing radiation or
contrast media. Standardized ultrasonography techniques
limit the sensitivity issues previously associated with
ultrasonography [38]. However, a consensus on stan-
dardization of venous ultrasound as an endpoint outcome
is still needed [39].
Risk assessment of acutely ill medical patients is
important to allow physicians to prescribe appropriate
anticoagulant therapy. In clinical trials of thrombopro-
phylaxis in acutely ill medical patients, variation exists
between the VTE risk factors used as patient inclusion
criteria. When the MAGELLAN study protocol was
designed, careful consideration was given to which VTE
risk-factor-related inclusion criteria were most appropriate.
Acute medical illnesses and predisposing risk factors
(e.g. age or previous VTE) were selected based on pub-
lished randomized controlled trials and other types of
studies.
This study, which is recruiting from 52 countries and
includes centers in Asia, Europe, North America, and
Africa, will provide a unique opportunity to evaluate the
risk of VTE and the potential beneﬁts of extended-duration
thromboprophylaxis in a truly multinational patient
population.
Other than the EXCLAIM study [40], MAGELLAN is
the only study in this patient population (completed or
ongoing) to include patients with active cancer and acute
ischemic stroke—conditions associated with a high risk of
VTE [12, 13]. Cancer in particular is a major risk factor,
with up to one in ﬁve diagnosed cases of VTE occurring in
a person with cancer [41]. Because of the large number of
patients in this study, MAGELLAN will also provide data
on VTE epidemiology in subgroups of patients where there
is little data, i.e. patients with acute infection or heart
failure.
MAGELLAN will provide further evidence as to
whether extended-duration therapy is more effective than
standard-duration therapy in a diverse population of
acutely ill medical patients. Furthermore, it will provide
information on the efﬁcacy, safety, and pharmacologic
proﬁle of the oral anticoagulant rivaroxaban in this patient
population, as well as health economics outcome research
data. Extended-duration therapy with a well-tolerated and
effective oral anticoagulant given once daily has the
potential to simplify thromboprophylaxis in acutely ill
medical patients, particularly during the post-hospital-
discharge period. This could improve patient compliance
and physician adherence to guidelines, ultimately reducing
VTE-associated morbidity and mortality.
Addendum
The protocol amendments described were implemented in
response to regulatory authority requests, to comply with
local regulations and requirements, or to comply with
labeling requirements.
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